Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome.
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000150:complications; D001627:Bethanidine / Q000627:therapeutic use; D001794:Blood Pressure; D003000:Clonidine / Q000627:therapeutic use; D006143:Guanabenz / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008750:Methyldopa / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications; D011311:Pressoreceptors / Q000503:physiopathology; D011446:Prospective Studies; D013375:Substance Withdrawal Syndrome; D013577:Syndrome; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D008750:Methyldopa; D006143:Guanabenz; D003000:Clonidine; D001627:Bethanidine